Wells Fargo & Company Adc Therapeutics Sa Transaction History
Wells Fargo & Company
- $407 Billion
- Q2 2024
A detailed history of Wells Fargo & Company transactions in Adc Therapeutics Sa stock. As of the latest transaction made, Wells Fargo & Company holds 25,704 shares of ADCT stock, worth $79,682. This represents 0.0% of its overall portfolio holdings.
Number of Shares
25,704Holding current value
$79,682% of portfolio
0.0%Shares
5 transactions
Others Institutions Holding ADCT
# of Institutions
79Shares Held
52.9MCall Options Held
300KPut Options Held
59.3K-
Redmile Group, LLC San Francisco, CA15.3MShares$47.3 Million3.15% of portfolio
-
Prosight Management, LP Dallas, TX9.57MShares$29.7 Million9.45% of portfolio
-
Orbimed Advisors LLC San Diego, CA4.32MShares$13.4 Million0.33% of portfolio
-
Black Rock Inc. New York, NY3.55MShares$11 Million0.0% of portfolio
-
Morgan Stanley New York, NY2.97MShares$9.19 Million0.0% of portfolio
About ADC Therapeutics SA
- Ticker ADCT
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 77,645,296
- Market Cap $241M
- Description
- ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYNLONTA that is in Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma;...